OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers

BACKGROUND: Anti-tumoral immunotherapy of anti-program death-1/program death-ligand 1 (PD-1/PD-L1) immune checkpoint therapy demonstrated promising efficacy and tolerability in patients with lung cancer. Apart from inhibitory checkpoints, OX40, the co-stimulatory receptor related to T cell priming a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Transl Lung Cancer Res
Autors principals: He, Yayi, Zhang, Xiaoshen, Jia, Keyi, Dziadziuszko, Rafal, Zhao, Sha, Deng, Juan, Wang, Hao, Hirsch, Fred R., Zhou, Caicun
Format: Artigo
Idioma:Inglês
Publicat: AME Publishing Company 2019
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6749115/
https://ncbi.nlm.nih.gov/pubmed/31555511
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr.2019.08.15
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars